Anti-LRP4 myasthenia gravis (MG): clinical features
Evidence-based neurology checklist on anti-lrp4 myasthenia gravis (mg): clinical features: Pathology LRP4 is the agrin receptor needed to activate MuSK It is present in 9-90% of double-seronegative patients It may co-exist with anti AchR and MUSK antibody MG Clinical features Outcome Acronym
Pathology
- LRP4 is the agrin receptor needed to activate MuSK
- It is present in 9-90% of double-seronegative patients
- It may co-exist with anti AchR and MUSK antibody MG
Clinical features
Outcome
Acronym
References
- Sieb JP. Myasthenia gravis: an update for the clinician. Clin Exp Immunol 2014; 175:408-418.
- Pevzner A, Schoser B, Peters K et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012; 259:427–35.
- Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012; 69:445–451.
- Nikolic AV, Bojic SD, Rakocevic Stojanovic VM, Basta IZ, Lavrnic DV. Electrophysiological findings in patients with low density lipoprotein receptor related protein 4 positive myasthenia gravis. Eur J Neurol 2016; 23:1635-1641.
- Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 2014; 52:139-145.
- And 3 more. Subscribe to see the full list
